Peritoneal dialysis treatment of metformin-associated lactic acidosis in a diabetic nephropathy patient

2016 ◽  
Vol 86 (11) ◽  
pp. 279-282 ◽  
Author(s):  
Jianjun Gao ◽  
Zhaoyan Gu ◽  
Yongxing Xu ◽  
Yu Na
Keyword(s):  
Diabetic Nephropathy ◽  
Peritoneal Dialysis ◽  
Lactic Acidosis ◽  
Dialysis Treatment ◽  
Diabetic Nephropathy Patient

The past and the present of peritoneal dialysis treatment

2008 ◽  
Vol 149 (1) ◽  
pp. 5-11 ◽  
Author(s):  
Kálmán Polner
Keyword(s):  
Peritoneal Dialysis ◽  
Dialysis Treatment ◽  
The Past

A szerző rövid áttekintést ad a peritonealis dialíziskezelés történetéről, kiemelve két magyar nefrológus, Stephen I. Vas és Taraba István munkásságának jelentőségét. A peritonealis dialíziskezelés fejlődése oda vezetett, hogy mára a hemodialízissel egyenrangú vesepótló kezelés lett. A maradék vesefunkció megőrzésével az első két évben a morbiditási, mortalitási mutatók és a betegek életminősége vonatkozásában felül is múlja azt. Gazdasági szempontból egyértelműen előnyösebb a hemodialízisnél, ezért az egyre több veseelégtelen beteg ellátásában várhatóan még nagyobb szerepet fog kapni. Az utóbbi években a technológia fejlődése és az automata peritonealis dialíziskezelések elterjedése is a minőség javítását segíti. A peritonealis dialíziskezelés a beteg önkezelése révén új kapcsolatrendszert alakít ki a betegek és az egészségügyi személyzet között, fokozódik a betegoktatás igénye, javul a betegek önbecsülése, együttműködése, ami összességében jobb rehabilitációs esélyeket és jobb életminőséget eredményez. A hazai peritonealis dialíziskezelés még elmarad az európai átlagtól, de a fejlődés dinamikus, és várhatóan a betegek száma is tovább fog növekedni.

Chronic Induction of C-Reactive Protein by Hemodialysis, but Not by Peritoneal Dialysis Therapy

1996 ◽  
Vol 16 (2) ◽  
pp. 158-162 ◽  
Author(s):  
Marion Haubitz ◽  
Reinhard Brunkhorst ◽  
Eike Wrenger ◽  
Peter Froese ◽  
Matthias Schulze ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Renal Insufficiency ◽  
Chronic Renal Insufficiency ◽  
Inflammatory Activity ◽  
C Reactive Protein ◽  
Dialysis Therapy ◽  
Dialysis Treatment ◽  
Reactive Protein ◽  
Before And After ◽  
Patient Groups

Objective Evaluation of the inflammatory activity in patients on chronic peritoneal dialysis (PD) and patients on chronic hemodialysis (HD) in comparison to patients with chronic renal insufficiency without dialysis treatment and healthy volunteers. Design Open, non randomized prospective study. Setting Nephrology Department, including HD and PD therapy in a university hospital. Patients Twenty -four patients on chronic PD, 21 patients on chronic HD therapy using a cuprophan dialyzer, 16 patients with chronic renal insufficiency without dialysis treatment, and 33 healthy volunteers; 8 additional patients before and after initiation of chronic HD therapy. All patients and controls were without infection or immunosuppressive therapy. Main Outcome Measures As a marker of the inflammatory activity in the different patient groups, C-reactive protein (CAP) was measured serially using a sensitive, enzyme-Iinked, immunosorbent assay in order to detect values below the detection limit of standard assays. Results All patient groups had CAP levels higher than the normal controls (p < 0.01). Patients on HD had CAP levels significantly higher than PD patients (p < 0.01) whose levels were comparable to patients without dialysis therapy. Accordingly, longitudinal measurements before and after initiation of chronic HD showed a significant increase in CAP levels after the beginning of HD treatment (p < 0.04). Conclusions The results suggest that induction of the inflammatory activity is lower during PD compared to HD, since stimulation by the dialyzer membrane, dialysate buffer, or bacterial fragments in the dialysate is avoided. This observation might indicate a possible lower risk of long-term complications in patients with PD.

Assessment of Liver Ability to Biotransformation of Antipyrine in Uraemic Patients on Regular Peritoneal Dialysis Treatment

1989 ◽  
pp. 413-415
Author(s):  
A. Grzegorzewska ◽  
Z. Łowicki ◽  
E. Chmara ◽  
A. Mrozikiewicz ◽  
K. Bączyk
Keyword(s):  
Peritoneal Dialysis ◽  
Dialysis Treatment

A Comparison of Bone Scans in Uremic Patients Treated with Intermittent Peritoneal Dialysis Or Hemodialysis

1996 ◽  
Vol 16 (1_suppl) ◽  
pp. 312-317
Author(s):  
Hanna Plotast ◽  
Alicja E. Grzegorzewska ◽  
Roman Junik ◽  
Jerzy Sowinski ◽  
Maciej Gernbicki
Keyword(s):  
Peritoneal Dialysis ◽  
Normal Limit ◽  
Cranial Vault ◽  
Entire Group ◽  
Similar Frequency ◽  
Dialysis Treatment ◽  
Younger Age ◽  
Uremic Patients ◽  
Bone Scans ◽  
Sacral Bone

The aim of the study was a comparative analysis of bone scans in uremic patients treated with intermittent peritoneal dialysis (IPD) or hemodialysis (HD). Bone scintigraphy was performed using technetium Tc 99m etidronate (EHDP) in 28 uremics (age 46.0±13.5 years, x±SD) on IPD for 3.1±3.0 months and 28 uremics (age 43.5±11.6 years) on HD for 47.3±33.9 months. Serum c terminal parathormone (cPTH) exceeded 5.3±3.3 and 6.8±3.5 times the upper normal limit of 1.4 ng/mL in IPD and HD patients, respectively. Despite significant differences in dialysis treatment duration in IPD and HD patients, an increased Tc 99m EHDP uptake in bones was shown with similar frequency, when all the groups were compared. However, in the group of patients with serum cPTH exceeding four times the upper normal limit (n = 30) or in the age group less than 45 years old (n = 26), a greater marker uptake was observed in HD patients. Significant differences (p < 0.05) were shown in the cranial vault: 33% of HD patients (n = 18) with higher cPTH and 47% of those less than 45 years old (n = 15) revealed an increased marker uptake, whereas it was not observed in any IPD patient. When scans of HD patients dialyzed less than (n = 11) and more than (n = 17) 30 months were compared, a significantly higher appearance of increased marker uptake was shown in cranial vault (41% vs 0%, p < 0.02) and in sacral bone (82% vs 36%, p < 0.02) in patients with longer dialysis. The latter group of HD patients also showed an increased marker uptake in cranial vault compared to the entire group of PD patients (41% vs 7%, p < 0.01). Our studies suggest that bone scan changes, indicating secondary hyperparathyroidism, progress significantly with prolongation of dialysis treatment, especially in patients with higher cPTH levels of younger age.

scholarly journals Management of peritoneal dialysis under COVID-19: The experience in Sichuan Province People’s Hospital, China

2020 ◽  
pp. 089686082093529 ◽  
Author(s):  
Jin Chen ◽  
Lijuan Yin ◽  
Xiuling Chen ◽  
Hui Gao ◽  
Qin Zhou ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Improve Patient Care ◽  
Patient Survey ◽  
Care Quality ◽  
Medical Support ◽  
Safety Measures ◽  
Dialysis Treatment ◽  
Medical Safety ◽  
Patient Care Quality ◽  
Improve Patient

The outbreak of coronavirus disease 2019 (COVID-19) is becoming a severe challenge to China and the whole world. By now, there is no report about medical support to peritoneal dialysis (PD) patient during COVID-19 pandemic. In this essay, we summed up our safety measures on how to protect PD patients and our staffs, and our experience on how to ensure the dialysis treatment of PD patients during the pandemic period. Using of telehealth has potential to improve patient care quality. As a result, by applying all the actions and efforts above, most of patients got enough medical support. According to the patient survey, 11 patients (3.3% of the total) reduced their treatment of dialysis exchange due to the shortage of PD solution or the affection of the pandemic. None of the PD patient and staff reported COVID-19. We successfully prevented COVID-19 transmission and ensured medical safety in our PD patients during the crisis.

Sign in / Sign up

Export Citation Format

Share Document